Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

TARGETED THERAPY

Activity of selpercatinib in RET fusion-positive cancers confirmed

Nature Reviews Clinical Oncology volume 19, page 747 (2022)Cite this article

Subjects

RET fusions are driver alterations found in several solid tumour types, including thyroid cancer subsets (5–10%), non-small-cell lung cancer (NSCLC; 1–2%) and other solid tumour types (<1%). In the phase I/II LIBRETTO-001 trial, the RET kinase inhibitor selpercatinib showed activity in selected RET fusion-positive cancers, leading to an FDA Accelerated Approval of this drug for patients aged ≥12 years with RET fusion-positive thyroid cancer or NSCLC. Now, updated data from this trial confirm the efficacy of selpercatinib in NSCLC and show promising activity in other types of RET fusion-positive solid tumours.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

References

Original articles

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Clinical Oncology http://www.nature.com/nrclinonc

    Diana Romero

Authors
  1. Diana Romero
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Diana Romero.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Romero, D. Activity of selpercatinib in RET fusion-positive cancers confirmed. Nat Rev Clin Oncol 19, 747 (2022). https://doi.org/10.1038/s41571-022-00694-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41571-022-00694-2

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer